Open AccessImmunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in HIV-infected individuals naive to pneumococcal vaccination
Author(s) -
As’ad E. Bhorat,
Shabir А. Madhi,
Vani Sundaraiyer,
Alejandra Gurtman,
Kathrin U. Jansen,
Daniel A. Scott,
Emilio A. Emini,
William C. Gruber,
Beate Schmöele-Thoma
Publication year - 2015
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/qad.0000000000000689
Subject(s) - immunogenicity , pneumococcal conjugate vaccine , medicine , vaccination , virology , pneumococcal infections , pneumococcal vaccine , streptococcus pneumoniae , immunology , antibody , biology , microbiology and biotechnology , antibiotics
Immunocompromised individuals are at an increased risk of pneumococcal disease. Vaccination is recommended as an important strategy to reduce risk of pneumococcal disease in HIV-infected individuals. This study evaluated the safety and immunogenicity of three 13-valent pneumococcal conjugate vaccine (PCV13) doses followed by one dose of 23-valent pneumococcal polysaccharide vaccine (PPSV23) at 1-month intervals in pneumococcal vaccine-naive, HIV-infected individuals.